The Effective Targeting of KRASG12C Elusiveness

被引：1

作者：

Elez, Filiation Elena ^{[1
]}

Tabernero, Josep ^{[1
]}

机构：

[1] Univ Autonoma Barcelona UAB, Dept Med Oncol, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

来源：

CANCER CELL | 2020年 / 38卷 / 06期

关键词：

MECHANISM; KRAS;

D O I：

10.1016/j.ccell.2020.11.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Developing therapies to directly target KRAS is challenging. In The New England Journal of Medicine, Hong et al. report a promising KRAS-targeting therapy phase I trial. However, a deeper understanding of the underlying biology of each histological context might well be required to optimize the potential benefit of this class of agents.

引用

页码：785 / 787

页数：3

共 11 条

[1] EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
Amodio, Vito
Yaeger, Rona
Arcella, Pamela
Cancelliere, Carlotta
Lamba, Simona
Lorenzato, Annalisa
Arena, Sabrina
Montone, Monica
Mussolin, Benedetta
Bian, Yu
Whaley, Adele
Pinnelli, Marika
Murciano-Goroff, Yonina R.
Vakiani, Efsevia
Valeri, Nicola
Liao, Wei-Li
Bhalkikar, Anuja
Thyparambil, Sheeno
Zhao, Hui-Yong
de Stanchina, Elisa
Marsoni, Silvia
Siena, Salvatore
Bertotti, Andrea
Trusolino, Livio
Li, Bob T.
Rosen, Neal
Di Nicolantonio, Federica
Bardelli, Alberto
Misale, Sandra
[J]. CANCER DISCOVERY, 2020, 10 (08) : 1129 - 1139
[2] The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Canon, Jude
Rex, Karen
Saiki, Anne Y.
Mohr, Christopher
Cooke, Keegan
Bagal, Dhanashri
Gaida, Kevin
Holt, Tyler
Knutson, Charles G.
Koppada, Neelima
Lanman, Brian A.
Werner, Jonathan
Rapaport, Aaron S.
San Miguel, Tisha
Ortiz, Roberto
Osgood, Tao
Sun, Ji-Rong
Zhu, Xiaochun
McCarter, John D.
Volak, Laurie P.
Houk, Brett E.
Fakih, Marwan G.
O'Neil, Bert H.
Price, Timothy J.
Falchook, Gerald S.
Desai, Jayesh
Kuo, James
Govindan, Ramaswamy
Hong, David S.
Ouyang, Wenjun
Henary, Haby
Arvedson, Tara
Cee, Victor J.
Lipford, J. Russell
[J]. NATURE, 2019, 575 (7781) : 217 - +
[3] Targeting the MAPK Pathway in KRAS-Driven Tumors
Drosten, Matthias
Barbacid, Mariano
[J]. CANCER CELL, 2020, 37 (04) : 543 - 550
[4] KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, David S.
Fakih, Marwan G.
Strickler, John H.
Desai, Jayesh
Durm, Gregory A.
Shapiro, Geoffrey I.
Falchook, Gerald S.
Price, Timothy J.
Sacher, Adrian
Denlinger, Crystal S.
Bang, Yung-Jue
Dy, Grace K.
Krauss, John C.
Kuboki, Yasutoshi
Kuo, James C.
Coveler, Andrew L.
Park, Keunchil
Kim, Tae Won
Barlesi, Fabrice
Munster, Pamela N.
Ramalingam, Suresh S.
Burns, Timothy F.
Meric-Bernstam, Funda
Henary, Haby
Ngang, Jude
Ngarmchamnanrith, Gataree
Kim, June
Houk, Brett E.
Canon, Jude
Lipford, J. Russell
Friberg, Gregory
Lito, Piro
Govindan, Ramaswamy
Li, Bob T.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (13) : 1207 - 1217
[5] Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, David M.
Puzanov, Igor
Subbiah, Vivek
Faris, Jason E.
Chau, Ian
Blay, Jean-Yves
Wolf, Juergen
Raje, Noopur S.
Diamond, Eli L.
Hollebecque, Antoine
Gervais, Radj
Elena Elez-Fernandez, Maria
Italiano, Antoine
Hofheinz, Ralf-Dieter
Hidalgo, Manuel
Chan, Emily
Schuler, Martin
Lasserre, Susan Frances
Makrutzki, Martina
Sirzen, Florin
Veronese, Maria Luisa
Tabernero, Josep
Baselga, Jose
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08) : 726 - 736
[6] Jänne PA, 2020, EUR J CANCER, V138, pS1
[7] Johnson M.L., 2020, EUR J CANCER, V138S2, pS1
[8] Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, Dongsung
Xue, Jenny Yaohua
Lito, Piro
[J]. CELL, 2020, 183 (04) : 850 - 859
[9] Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, Jonathan M. L.
Shokat, Kevan M.
[J]. NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (11) : 771 - 785
[10] The Frequency of Ras Mutations in Cancer
Prior, Ian A.
Hood, Fiona E.
Hartley, James L.
[J]. CANCER RESEARCH, 2020, 80 (14) : 2969 - 2974

← 1 2 →